The presence of progesterone receptor (PR) in breast tumors indicates an increased likelihood of response to anti-estrogen (tamoxifen) therapy. The Progesterone Receptor [SP2] antibody clone is a high affinity rabbit monoclonal. A study has shown that the SP2 clone had a much higher affinity as compared to mouse monoclonals for the progesterone receptor. Studies have also shown that the SP2 clone provides supplementary evidence to ER in predicting survival in human breast cancer.
There are no reviews yet.